Abstract
Renal artery stenting for Atherosclerotic renovascular disease (ARVD) has been a subject of debate for the last two decades. A subset of patients with severe ARVD and large renal mass involvement, who were misrepresented in latest large clinical trials, could gain benefit from this strategy. This is
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
